Corvus Pharmaceuticals
CRVS
54 hedge funds and large institutions have $280M invested in Corvus Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
32% more capital invested
Capital invested by funds: $212M → $280M (+$67.9M)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
4% more funds holding
Funds holding: 52 → 54 (+2)
0.19% more ownership
Funds ownership: 83.59% → 83.78% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.56M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.43M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.18M |
| 4 |
Renaissance Technologies
New York
|
+$791K |
| 5 |
TI
Telemetry Investments
New York
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.71M |
| 2 |
Jennison Associates
New York
|
-$1.75M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$535K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$517K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$501K |
CRVS Hedge Fund Activity: Q3 2017 in Review
54 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2017, worth a combined $280M — up 32% from $212M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CRVS positions and 3 closed out — a net gain of 3 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was BVF Inc, adding an estimated $2.56M. The largest seller was Fidelity Investments, cutting an estimated $2.71M.
- 54 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2017, up from 52 in Q2 2017.
- Funds reported $280M of Corvus Pharmaceuticals stock for Q3 2017, up 32% quarter-over-quarter.
- 6 funds opened new Corvus Pharmaceuticals positions in Q3 2017 and 3 closed out, a net change of +3 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2017 was BVF Inc, an estimated $2.56M added.
- The largest Corvus Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $2.71M sold.
Based on aggregated 13F filings for Q3 2017.